ClinicalTrials.gg
CompletedNCT02623140SORT OUT IXUpdated Oct 22, 2026

BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX

An interventional study of Biofreedom and Orsiro in Ischaemic Heart Disease, sponsored by Odense University Hospital. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Coronary Artery Disease by Odense University Hospital — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Odense University Hospital.

Enrollment
Largest of 11
3,150 · median 104
Started
2015
the only one that year
No phase
10 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies in Coronary Artery Disease by Odense University Hospital, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 10 with no phase, and was the 7th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 14 studies in Coronary Artery Disease by Odense University Hospital is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Coronary Artery Disease by Odense University Hospital, or all of them as a file.
02

Study summary

The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the polymer-free Biolimus-eluting BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting ORSIRO stent in a population-based setting, using registry detection of clinically driven events

Read the detailed description

SORT OUT IX is a randomized, multicenter, all-comer, two-arm, non-inferiority trial comparing the polymer-free Biolimus-eluting BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting ORSIRO stent in treating atherosclerotic coronary artery lesions.

Patients will be enrolled by the investigators and randomly allocated to treatment groups after diagnostic coronary angiography and before percutaneous coronary intervention. Block randomization by centre (permuted blocks of random sizes (2/4/6)) will be used to assign patients in a 1:1 ratio to receive the polymer-free Biolimus-eluting BIOFREEDOM stent (Biosensors) or the biodegradable-polymer Sirolimus-eluting ORSIRO stent (Biotronik). A web based Trial Partner randomization system will be used.

03

Conditions studied

  • Ischaemic Heart Disease

Keywords

  • Coronary drug eluting stents
  • Outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or over with chronic stable coronary artery disease or acute coronary syndromes, and at least one coronary artery lesion with more than 50% diameter stenosis, requiring treatment with a drug-eluting stent.

Exclusion criteria

Exclusion Criteria:

  • of less than one year; an allergy to aspirin, clopidogrel, ticagrelor, prasugral, biolimus or sirolimus; participation in another randomized trial; or inability to provide written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,150 participants (actual)

Study arms

  • Experimental
    Biofreedom

    Biofreedom stent treatment at index procedure

    Device: Biofreedom

  • Active comparator
    Orsiro

    Orsiro stent treatment at index procedure

    Device: Orsiro

Interventions

  • DeviceBiofreedom

    PCI with Biofreedom stent

  • DeviceOrsiro

    PCI with Orsiro stent

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure

    Primary endpoint assessed after 12 months

    Time frame: 12 months

Secondary outcomes

  1. Target lesion failure

    Target lesion failure will be assessed yearly up to 5 years after index procedure

    Time frame: 2 year, 3 year, 4 year, 5 year

  2. Stent thrombosis

    Stent thrombosis will be assessed yearly up to 5 years after index procedure

    Time frame: 1 year, 2 years, 3 years, 4 years, 5 years

  3. Myocardial infarction

    Myocardial infarction will be assessed yearly up to 5 years after index procedure

    Time frame: 1 year, 2 years, 3 years, 4 years, 5 years

  4. Cardiac death

    Cardiac death will be assessed yearly up to 5 years after index procedure

    Time frame: 1 year, 2 years, 3 years, 4 years, 5 years

  5. All cause mortality

    All cause mortality will be assessed yearly up to 5 years after index procedure

    Time frame: 1 year, 2 years, 3 years, 4 years, 5 years

  6. Target lesion revascularization

    Target lesion revascularization will be assessed yearly up to 5 years after index procedure

    Time frame: 1 year, 2 years, 3 years, 4 years, 5 years

  7. Target vessel revascularization

    Target vessel revascularization will be assessed yearly up to 5 years after

    Time frame: 1 year, 2 years, 3 years, 4 years, 5 years

07

Study locations

1 site
  • Odense University Hospital
    Odense, 5000, Denmark
08

References and documents

Publications

  • Jensen Lisette Okkels, Maeng M, Raungaard B, Kahlert J, Ellert J, Jakobsen L, Villadsen AB, Veien KT, Kristensen SD, Ahlehoff O, Carstensen S, Christensen MK, Terkelsen CJ, Engstroem T, Hansen KN, Botker HE, Aaroe J, Thim T, Thuesen L, Freeman P, Aziz A, Eftekhari A, Junker A, Jensen SE, Lassen JF, Hansen HS, Christiansen EH; Sort Out IX Study Group. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial. Circulation. 2020 Jun 23;141(25):2052-2063. doi: 10.1161/CIRCULATIONAHA.119.040241. Epub 2020 May 21. PubMed 32434381 ↗
  • Jensen LO, Maeng M, Raungaard B, Engstrom T, Hansen HS, Jensen SE, Botker HE, Kahlert J, Lassen JF, Christiansen EH. Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomized SORT OUT IX trial. Am Heart J. 2019 Jul;213:1-7. doi: 10.1016/j.ahj.2019.02.017. Epub 2019 Mar 14. PubMed 31055192 ↗
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Oct 2018 and a completion of Oct 2023. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2015
First posted
Dec 7, 2015
Start
Dec 2015
Primary completionActual
Oct 1, 2018
CompletionActual
Oct 1, 2023
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 22, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
Oct 22, 2026
Design
Phase 4→Not applicable
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Completed
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
    Design Phase 4→Not applicable
    + 3 other changes: verification date, date precision and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02623140
Collaborators
Aarhus University Hospital Skejby, Aalborg University Hospital, Copenhagen University Hospital, Rigshospitalet
Responsible party
Lisette Okkels Jensen (MD DMSci PhD, Odense University Hospital) — Principal investigator
First posted
Dec 7, 2015
Start date
Dec 2015
Primary completion
Oct 1, 2018
Completion
Oct 1, 2023
Last update
Oct 22, 2026

Study contacts

Lisette Okkels Jensen, MD DMSci PhD
study chair · Odense University Hospital
Evald H Christiansen, MD PhD
study chair · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion